[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fFdaGmNsBgf9E6CflSpoDWUq71nglqUHtSzkeo5xpJG8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"French Cardiology Society",[4],81,false,16,4,60986,2,72,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"Heart Failure",8,{"name":18,"count":9},"Myocardial Infarction",{"name":20,"count":21},"Atrial Fibrillation",3,{"name":23,"count":21},"Acute Coronary Syndrome",{"name":25,"count":21},"Cardiovascular Diseases",{"name":27,"count":21},"Acute Myocardial Infarction",{"name":29,"count":11},"Pericardial Effusion",{"name":31,"count":11},"Heart Decompensation",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT07372859","Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female Runners","2026-09-30","Blood sampling",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,71,89,115,140,166,184,209,232,257,275,299],{"intervention":37,"totalTrials":47,"cells":48},1,{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":60},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":51},[],{"trials":59,"activeCount":51},[],{"trials":61,"activeCount":47,"soonestReadout":36},[62],{"nctId":34,"briefTitle":35,"status":63,"phases":64,"primaryCompletion":36,"completion":36,"start":65,"enrollment":66,"conditions":67,"interventions":69},"NOT_YET_RECRUITING",[44],"2026-03-22",120,[68],"Healthy Volunteer",[37,70],"Urinary test",{"intervention":70,"totalTrials":47,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":83},{"trials":74,"activeCount":51},[],{"trials":76,"activeCount":51},[],{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":51},[],{"trials":82,"activeCount":51},[],{"trials":84,"activeCount":47,"soonestReadout":36},[85],{"nctId":34,"briefTitle":35,"status":63,"phases":86,"primaryCompletion":36,"completion":36,"start":65,"enrollment":66,"conditions":87,"interventions":88},[44],[68],[37,70],{"intervention":90,"totalTrials":47,"cells":91},"diclofenac",{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":100,"NA":113},{"trials":93,"activeCount":51},[],{"trials":95,"activeCount":51},[],{"trials":97,"activeCount":51},[],{"trials":99,"activeCount":51},[],{"trials":101,"activeCount":51},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT00247052","Non Steroidal Anti Inflammatory Treatment for Post Operative Pericardial Effusion","COMPLETED",[43],"2008-12","2009-02","2006-03",200,[29],[90,90],{"trials":114,"activeCount":51},[],{"intervention":116,"totalTrials":47,"cells":117},"Colchicines",{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":138},{"trials":119,"activeCount":51},[],{"trials":121,"activeCount":51},[],{"trials":123,"activeCount":51},[],{"trials":125,"activeCount":51},[],{"trials":127,"activeCount":51},[128],{"nctId":129,"briefTitle":130,"status":105,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT01266694","Cochicine Treatment for Post- Operative Pericardial Effusion",[43],"2013-03","2014-01","2011-04",199,[29],[116],{"trials":139,"activeCount":51},[],{"intervention":141,"totalTrials":47,"cells":142},"dose adaptation of Enoxaparin",{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":164},{"trials":144,"activeCount":51},[],{"trials":146,"activeCount":51},[],{"trials":148,"activeCount":51},[],{"trials":150,"activeCount":51},[],{"trials":152,"activeCount":51},[153],{"nctId":154,"briefTitle":155,"status":105,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":162},"NCT00412802","Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome",[43],"2009-03","2006-12",67,[23,161],"Renal Failure",[141,163],"normal injection of Enoxaparine",{"trials":165,"activeCount":51},[],{"intervention":163,"totalTrials":47,"cells":167},{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":176,"NA":182},{"trials":169,"activeCount":51},[],{"trials":171,"activeCount":51},[],{"trials":173,"activeCount":51},[],{"trials":175,"activeCount":51},[],{"trials":177,"activeCount":51},[178],{"nctId":154,"briefTitle":155,"status":105,"phases":179,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":180,"interventions":181},[43],[23,161],[141,163],{"trials":183,"activeCount":51},[],{"intervention":185,"totalTrials":47,"cells":186},"Acid Nicotinique",{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":205,"NA":207},{"trials":188,"activeCount":51},[],{"trials":190,"activeCount":51},[],{"trials":192,"activeCount":51},[],{"trials":194,"activeCount":51},[195],{"nctId":196,"briefTitle":197,"status":105,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT00855257","Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome",[42],"2009-05","2007-06",93,[203],"Acute Coronary Syndrome (ACS)",[185],{"trials":206,"activeCount":51},[],{"trials":208,"activeCount":51},[],{"intervention":210,"totalTrials":47,"cells":211},"Atorvastatin 40mg",{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":228,"NA":230},{"trials":213,"activeCount":51},[],{"trials":215,"activeCount":51},[],{"trials":217,"activeCount":51},[],{"trials":219,"activeCount":51},[220],{"nctId":221,"briefTitle":222,"status":105,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":66,"conditions":226,"interventions":227},"NCT03837925","Pharmaco-metabolomic Effects of Statins: METASTATINE",[42],"2022-12-21","2019-06-13",[25],[210],{"trials":229,"activeCount":51},[],{"trials":231,"activeCount":51},[],{"intervention":233,"totalTrials":47,"cells":234},"morphine chlorhydrate",{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":253,"NA":255},{"trials":236,"activeCount":51},[],{"trials":238,"activeCount":51},[],{"trials":240,"activeCount":51},[],{"trials":242,"activeCount":51},[243],{"nctId":244,"briefTitle":245,"status":105,"phases":246,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":251},"NCT01186445","Morphine In Acute Myocardial Infarction",[42],"2016-12","2011-01",94,[27],[233,252],"saline solution",{"trials":254,"activeCount":51},[],{"trials":256,"activeCount":51},[],{"intervention":252,"totalTrials":47,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":271,"NA":273},{"trials":260,"activeCount":51},[],{"trials":262,"activeCount":51},[],{"trials":264,"activeCount":51},[],{"trials":266,"activeCount":51},[267],{"nctId":244,"briefTitle":245,"status":105,"phases":268,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":269,"interventions":270},[42],[27],[233,252],{"trials":272,"activeCount":51},[],{"trials":274,"activeCount":51},[],{"intervention":276,"totalTrials":47,"cells":277},"catch of blood",{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":288},{"trials":279,"activeCount":51},[],{"trials":281,"activeCount":51},[],{"trials":283,"activeCount":51},[],{"trials":285,"activeCount":51},[],{"trials":287,"activeCount":51},[],{"trials":289,"activeCount":51},[290],{"nctId":291,"briefTitle":292,"status":105,"phases":293,"primaryCompletion":294,"completion":294,"start":107,"enrollment":295,"conditions":296,"interventions":298},"NCT00799565","Mitral Valve Prolapse (MVP) - France Study",[44],"2011-07",1179,[297],"Mitral Valve Prolapse",[276],{"intervention":300,"totalTrials":47,"cells":301},"TGFBR2",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":312},{"trials":303,"activeCount":51},[],{"trials":305,"activeCount":51},[],{"trials":307,"activeCount":51},[],{"trials":309,"activeCount":51},[],{"trials":311,"activeCount":51},[],{"trials":313,"activeCount":51},[314],{"nctId":315,"briefTitle":316,"status":317,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":325},"NCT05146375","Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)","UNKNOWN",[],"2023-09-28","2025-11-30","2022-11-24",17,[324],"Thoracic Aortic Aneurysm",[300]]